Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Recursion Pharmaceuticals (RXRX)

Annual Return

Over the past 3 years, RXRX has had an average annual return of -24.06%, underperforming the benchmark SPY, which returned +22.77% annual.

Over the past 5 years, RXRX has had an average annual return of -34.33%, underperforming the benchmark SPY, which returned +14.05% annual.

Since Apr 16, 2021, RXRX has had an average annual return of -34.36%, underperforming the benchmark SPY, which returned +13.89% annual.

202620252024202320222021
-11.78%-39.49%-31.43%+27.89%-55.00%-45.27%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026+2.45%-12.40%-16.37%+12.64%+3.80%+0.52%-11.78%
2025+7.08%+3.72%-29.55%+5.68%-25.25%+21.12%+17.56%-20.99%+3.79%+13.15%-16.16%-11.63%-39.49%
2024-4.57%+43.05%-25.93%-21.57%+5.88%-9.41%+9.35%-11.22%-9.50%-4.09%+11.89%-4.38%-31.43%
2023+8.04%-2.14%-18.16%-28.48%+83.86%-14.81%+88.98%-38.37%-12.09%-30.97%+29.70%+43.97%+27.89%
2022-30.88%-7.53%-34.59%-13.42%-1.31%+33.04%+3.92%+24.23%+1.22%-0.82%-10.92%-17.98%-55.00%
2021+6.71%-21.08%+38.46%-16.85%-16.89%-8.77%-16.77%-0.15%-10.41%-45.27%

Drawdown analysis of Recursion Pharmaceuticals (RXRX)

The maximum drawdown for the RXRX was -93.13%, occurring on Mar 30, 2026. This drawdown has not yet recovered.

The current RXRX drawdown is -91.27%.

Since Apr 16, 2021 RXRX has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 2 times
  • 20% or more: 2 times
  • 10% or more: 4 times
DepthStartTo BottomBottomTo RecoverEndTotal
-93.13%Jul 13, 20211183Mar 30, 2026OngoingOngoingOngoing
-38.10%Apr 29, 202110May 13, 202124Jun 17, 202134
-10.54%Apr 16, 20211Apr 19, 20212Apr 21, 20213
-10.45%Jun 21, 20212Jun 23, 20218Jul 6, 202110
-8.29%Apr 21, 20212Apr 23, 20214Apr 29, 20216